Pazopanib is an investigational, oral, once-daily angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit. VEGF and PDGF are growth factors critical to the development and growth of blood vessels – a process known as angiogenesis. Angiogenesis plays a pivotal role in the growth and spread of several tumor types, with VEGF and PDGF overexpression linked to multiple cancers including cancers of the liver, lung, breast, kidney, bladder, ovaries, and colon. By inhibiting VEGFR, PDGFR, and c-kit, pazopanib may stop or slow the rate of tumor growth and development. Pazopanib is currently being studied in a number of different tumor types; clinical trials are currently underway in RCC, breast cancer, ovarian cancer, soft tissue sarcoma, NSCLC, cervical cancer and other solid tumors. It is being evaluated as a monotherapy, in combination with targeted therapies and in combination with cytotoxic chemotherapy.
The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.
Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.
In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery. This multidisciplinary approach is the focus of special symposia at the meetings of the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology (ESTRO) taking place in Sweden this month.
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.